Orlowski RZ - Search Results

1

Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

Kuhn DJ, Orlowski RZ, Bjorklund CC. Kuhn DJ, et al. Among authors: orlowski rz. Curr Cancer Drug Targets. 2011 Mar;11(3):285-95. doi: 10.2174/156800911794519725. Curr Cancer Drug Targets. 2011. PMID: 21247387 Review.

2

Proteasome inhibitors in cancer therapy.

Orlowski RZ. Orlowski RZ. Methods Mol Biol. 2005;301:339-50. doi: 10.1385/1-59259-895-1:339. Methods Mol Biol. 2005. PMID: 15917644 Review.

3

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.

Ryan DP, O'Neil BH, Supko JG, Rocha Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Cusack JC Jr. Ryan DP, et al. Among authors: orlowski rz. Cancer. 2006 Dec 1;107(11):2688-97. doi: 10.1002/cncr.22280. Cancer. 2006. PMID: 17075878 Free article. Clinical Trial.

4

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ. Kuhn DJ, et al. Among authors: orlowski rz. Blood. 2007 Nov 1;110(9):3281-90. doi: 10.1182/blood-2007-01-065888. Epub 2007 Jun 25. Blood. 2007. PMID: 17591945 Free PMC article.

5

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.

Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ. Voorhees PM, et al. Among authors: orlowski rz. Clin Cancer Res. 2007 Nov 1;13(21):6469-78. doi: 10.1158/1078-0432.CCR-07-1293. Clin Cancer Res. 2007. PMID: 17975159

6

Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.

Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Chen Q, et al. Among authors: orlowski rz. Blood. 2008 May 1;111(9):4690-9. doi: 10.1182/blood-2007-09-112904. Epub 2008 Feb 27. Blood. 2008. PMID: 18305219 Free PMC article.

7

Proteasome inhibitors in cancer therapy: lessons from the first decade.

Orlowski RZ, Kuhn DJ. Orlowski RZ, et al. Clin Cancer Res. 2008 Mar 15;14(6):1649-57. doi: 10.1158/1078-0432.CCR-07-2218. Clin Cancer Res. 2008. PMID: 18347166 Review.

8

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Kuhn DJ, et al. Among authors: orlowski m, orlowski rz. Blood. 2009 May 7;113(19):4667-76. doi: 10.1182/blood-2008-07-171637. Epub 2008 Dec 2. Blood. 2009. PMID: 19050304 Free PMC article.

9

Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ. Voorhees PM, et al. Among authors: orlowski rz. Br J Haematol. 2009 May;145(4):481-90. doi: 10.1111/j.1365-2141.2009.07647.x. Epub 2008 Mar 6. Br J Haematol. 2009. PMID: 19344406 Free PMC article.

10

Bortezomib and EGCG: no green tea for you?

Shah JJ, Kuhn DJ, Orlowski RZ. Shah JJ, et al. Among authors: orlowski rz. Blood. 2009 Jun 4;113(23):5695-6. doi: 10.1182/blood-2009-03-204776. Blood. 2009. PMID: 19498025 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

351 results

Search Page